AR099148A1 - HUMAN ANTIBODIES FOR PROGRAMMED DEATH IMMUNOMODULATOR RECEIVER-1 (PD-1) - Google Patents

HUMAN ANTIBODIES FOR PROGRAMMED DEATH IMMUNOMODULATOR RECEIVER-1 (PD-1)

Info

Publication number
AR099148A1
AR099148A1 ARP150100162A ARP150100162A AR099148A1 AR 099148 A1 AR099148 A1 AR 099148A1 AR P150100162 A ARP150100162 A AR P150100162A AR P150100162 A ARP150100162 A AR P150100162A AR 099148 A1 AR099148 A1 AR 099148A1
Authority
AR
Argentina
Prior art keywords
antibodies
programmed death
human antibodies
immunomodulator
receiver
Prior art date
Application number
ARP150100162A
Other languages
Spanish (es)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR099148A1 publication Critical patent/AR099148A1/en

Links

Abstract

La presente proporciona anticuerpos que se unen a la proteína muerte programada-1 (PD-1) co-inhibidor de células T, y métodos de uso. En diversas formas de realización de la presente, los anticuerpos son anticuerpos completamente humanos que se unen a PD-1. En ciertas formas de realización, se proporcionan moléculas de unión a antígeno multi-específicas que comprenden una primera especificidad de unión que se une a PD-1 y una segunda especificidad de unión que se une a un antígeno de tejido autoinmune, otro co-inhibidor de células T, un receptor de Fc o un receptor de células T. En algunas formas de realización, los anticuerpos de la invención son útiles para inhibir o neutralizar la actividad de PD-1, proporcionando así un medio para el tratamiento de una enfermedad o trastorno tal como cáncer o una infección viral crónica. En otras formas de realización, los anticuerpos son útiles para mejorar o estimular la actividad de PD-1, proporcionando así un medio para el tratamiento de, por ejemplo, un trastorno o enfermedad autoinmune.This provides antibodies that bind to the programmed death protein-1 (PD-1) co-inhibitor of T cells, and methods of use. In various embodiments of the present, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, multi-specific antigen binding molecules are provided that comprise a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another co-inhibitor of T cells, an Fc receptor or a T cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing the activity of PD-1, thereby providing a means for the treatment of a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for improving or stimulating the activity of PD-1, thus providing a means for the treatment of, for example, an autoimmune disorder or disease.

ARP150100162A 2014-01-23 2015-01-21 HUMAN ANTIBODIES FOR PROGRAMMED DEATH IMMUNOMODULATOR RECEIVER-1 (PD-1) AR099148A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461930576P 2014-01-23 2014-01-23

Publications (1)

Publication Number Publication Date
AR099148A1 true AR099148A1 (en) 2016-07-06

Family

ID=58698425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100162A AR099148A1 (en) 2014-01-23 2015-01-21 HUMAN ANTIBODIES FOR PROGRAMMED DEATH IMMUNOMODULATOR RECEIVER-1 (PD-1)

Country Status (2)

Country Link
AR (1) AR099148A1 (en)
MA (1) MA49604B1 (en)

Also Published As

Publication number Publication date
MA49604B1 (en) 2022-09-30
MA49604A1 (en) 2022-02-28

Similar Documents

Publication Publication Date Title
CY1124747T1 (en) HUMAN ANTIBODIES TO PD-1
CL2018000908A1 (en) Anti-lag3 antibodies and their use to treat cancer or viral infection.
CY1124437T1 (en) HUMAN ANTIBODIES AGAINST PD-L1
CL2022003763A1 (en) Human antibodies against Ebola virus glycoprotein
ECSP18019568A (en) ANTI-BCMA ANTIBODIES, AND USES OF BISpecific ANTIGENS BINDING MOLECULES THAT BIND BCMA AND CD3
CL2017000310A1 (en) Anti tigit antibodies
CY1121542T1 (en) ANTIBODY MOLECULES TO PD-1 AND THEIR USE
CO2019000968A2 (en) Zika anti-virus antibodies and methods of use
UY36757A (en) MONOCLONAL ANTIBODIES AGAINST CD40 WITH IMPROVED AGONIST ACTIVITY
CO2018001485A2 (en) Bispecific monovalent diabodies that are capable of binding to b7 - h3 and cd3
CL2017000515A1 (en) Cd123 linking agents and their use
CO2018000809A2 (en) Antibodies for cd40
PE20180484A1 (en) T-CELL ACTIVATING ANTIGEN-BINDING BI-SPECIFIC MOLECULES
BR112017013385A2 (en) antibodies to tigit
UY36458A (en) HUMAN ANTIBODIES FOR INFLUENZA HEMAGLUTININE.
ECSP15025845A (en) ANTI-CEACAM5 ANTIBODIES AND USES OF THEM
CO2019002671A2 (en) Anti-cd27 antibodies
TR201905909T4 (en) Combinations of anti-4-1bb antibodies and adcc inducing antibodies for cancer therapy.
NI201500002A (en) RSPO3 BINDING AGENTS AND USES OF THEM.
CO2020001981A2 (en) Proteins that bind to nkg2d, cd16, and flt3
UY37630A (en) PHARMACEUTICAL COMBINATION, KIT, GUEST CELL THAT PRODUCES IT AND ITS USE IN METHODS FOR CANCER TREATMENT
AR099148A1 (en) HUMAN ANTIBODIES FOR PROGRAMMED DEATH IMMUNOMODULATOR RECEIVER-1 (PD-1)
BR112017013420A2 (en) humanized adam17 antibody
AR099147A1 (en) HUMAN ANTIBODIES AGAINST PD-L1
ECSP17016755A (en) ANTI TIGIT ANTIBODIES